Idelalisib and Rituximab
About
Membership operator: AND
Therapies: 2
Therapies
Idelalisib (tx:ncit:C78825)
Rituximab (tx:ncit:C1702)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) | TP53 deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| EMA (1) | TP53 Somatic variants | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| EMA (1) | 17p deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab |